Skip to main content
Anke van den Berg
prof. dr.

I work as a clinical molecular biologist in the department of Pathology. In this function I supervise and implement advanced molecular diagnostic techniques. Within my research line, I focus on the molecular pathogenesis of B-cell Hodgkin and non-Hodgkin lymphoma. The specific fields of interest are genomic aberrations, genetic susceptibility, and the role of small and long noncoding RNAs. I have several international collaborations and am PI and co-PI in various projects.

Tgf beta-Smad Pathway And Extracellular Matrix Gene Expression Changes Related To COPD, Age And Gender In Airway And Parenchymal Lung Tissue
miRNAs in Medicine: The role of miRNAs in Hodgkin lymphoma
Studying microRNAs in lymphoma
Published in: Methods in Molecular Biology
MicroRNAs (miRNAs) play important roles in development, differentiation, homeostasis, and also in diseases such as lymphoma. This chapter describes methods to study the role of miRNAs in lymphoma. First, we describe a multiplex RT reaction followed by qPCR that can be used to determine differential expression of candidate miRNAs. Second, we provide a protocol for stable overexpression of miRNAs using lentiviral-based ectopic expression systems. Third, we describe a straightforward assay to determine whether the candidate miRNA may function as an oncogene or a tumor suppressor gene in lymphomagenesis.
Joost Kluiver, Izabella Slezak-Prochazka, Anke van den Berg
Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor
Published in: Annals of Oncology
BACKGROUND: Initial response of small-cell lung cancer (SCLC) to chemotherapy is high, and recurrences occur frequently, leading to early death. This study investigated the prognostic value of circulating tumor cells (CTCs) in patients with SCLC and whether changes in CTCs can predict response to chemotherapy. PATIENTS AND METHODS: In this multicenter prospective study, blood samples for CTC analysis were obtained from 59 patients with SCLC before, after one cycle, and at the end of chemotherapy. CTCs were measured using CellSearch® systems. RESULTS: At baseline, lower numbers of CTCs...
T J N Hiltermann, M M Pore, Anke van den Berg, W Timens, H M Boezen, J J W Liesker, J H Schouwink, W J A Wijnands, G S M A Kerner, F A E Kruyt, H Tissing, A G J Tibbe, L W M M Terstappen, H J M Groen
Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma
Published in: Blood
In classical Hodgkin lymphoma (CHL), 20%-30% of patients experience relapse or progressive disease after initial treatment. The pathogenesis and biology of treatment failure are still poorly understood, in part because the molecular phenotype of the rare malignant Hodgkin Reed-Sternberg (HRS) cells is difficult to study. Here we examined microdissected HRS cells from 29 CHL patients and 5 CHL-derived cell lines by gene expression profiling. We found significant overlap of HL-specific gene expression in primary HRS cells and HL cell lines, but also differences, including surface receptor signaling pathways....
Christian Steidl, Arjan Diepstra, Tang Lee, Fong Chun Chan, Pedro Farinha, King Tan, Adele Telenius, Lorena Barclay, Sohrab P. Shah, Joseph M. Connors, Anke van den Berg, Randy D. Gascoyne